While overall risks for adverse birth outcomes were not increased in children born to fathers who used disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, for autoimmune diseases in ...

A study conducted in Denmark showed that treatment of rheumatoid arthritis with disease modifying antirheumatic drugs (DMARDs), glucocorticoids, biologic agents, or a combination of agents ...

Patients with rheumatic conditions and opioid use disorder (OUD) have distinct demographic and clinical characteristics, ...

rheumatoid arthritis dmard vs biologic Updated American College of Rheumatology recommendations suggest using first-line DMARDs in combination with biologic agents and nonbiologic DMARDs to achieve ...

Please provide your email address to receive an email when new articles are posted on . Among patients with rheumatoid arthritis, observed rates of major adverse events from biologic/targeted ...

Nonsteroidal anti-inflammatory drugs and analgesics are frequently prescribed to alleviate symptoms in patients with RA. However, these medications have no impact on disease progression and therefore ...

Please provide your email address to receive an email when new articles are posted on . JAK inhibition carried higher malignancy risk vs. biologic DMARDs. Malignancy risk was seen in older patients ...

DMARDS can increase the chances of remission in patients with rheumatoid arthritis, even after DMARD usage is stopped, according to a Swedish study. Share on Pinterest Early treatment with ...

A cross-sectional study finds that patients with rheumatoid arthritis receiving disease-modifying antirheumatic drugs (DMARDs) exhibit a reduced immune response to the COVID-19 vaccine compared with ...

Advances in medication have changed ankylosing spondylitis treatment and may even change the progression of the disease. That’s welcome news for many people who deal with the pain and stiffness of ...

German study focused on cases referred to rheumatologists ...

The treat-to-target approach represented a stepped-up model for chronic disease management that only became possible when the available therapies showed the potential for disease remission. The ...